Personalized mRNA Melanoma Vaccine Reports Positive Phase 3 Outcomes
A personalized mRNA vaccine combined with pembrolizumab was reported to improve recurrence-free and distant metastasis-free survival in high-risk melanoma. Coverage lacks underlying figures and full trial results; longer follow-up and safety data are needed, and FDA approval is only anticipated for 2027.
Sources (2)
Updated Nov 20, 2026